Quality-of-Life Assessment + Questionnaire Administration + Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine for pulmonary disease, chronic obstructive

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Mar 2020: Trial registered, NCT04298606
  2. 22 Nov 2021: Trial started, NCT04298606

The trials

NCT04298606: A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

State
Completed
Phase
Early Phase 1
People
20 taking part
Started
22 Nov 2021
Primary completion
5 Dec 2025
Arms
Prevention (recombinant human EGF-rP64K/montanide ISA 51)
Results
None posted
  1. 6 Mar 2020: Trial registered
  2. 22 Nov 2021: Trial started
  3. 6 Feb 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.